

# Nurse Program

## 17th International Pulmonary Hypertension Forum

**ACHIEVE MORE – OPTIMIZING MANAGEMENT IN PAH**

**Madrid Marriott Auditorium  
Madrid, Spain | 23 – 25 March 2018**

**Scientific Committee:**

**Professor Marius M. Hoeper  
Professor Lewis Rubin**

**Professor Nazzareno Galiè**

**Professor Vallerie McLaughlin  
Professor Gérald Simonneau**

**Nurse Program Co-Chairs:**

**Wendy Gin-Sing**

**Martha Kingman**



**ACTELION**

A JANSSEN PHARMACEUTICAL COMPANY  
OF *Johnson & Johnson*

**Saturday, 24 March 2018**

**09:00–10:30 Plenary 1:**

**Patient assessment today for a better tomorrow**

**Co-Chairs:**  
**P Escribano, MM Hoeper**

- What is coming up in the next two days
- Choosing the right treatment strategy today – A case study
- A paradigm shift in patient assessment
- Disease progression and its impact – A call to action

MM Hoeper  
S Bartolome  
O Sitbon  
V McLaughlin

*10:30 – 11:00 Coffee break with poster exhibition*

**11:00 – 11:45 Interactive debate**

**Is RHC still a fundamental part of the follow-up assessment in PAH?**

**Moderator:**

- L Howard, M Humbert

R Frantz

**11:45 – 12:35 Plenary 2:**

**Present and future perspectives in PAH management**

**Co-Chairs:**  
**R Channick, A Frost**

- PAH management – State of the art after the 6th WSPH
- Beyond the three pathways – Future targets in PAH

N Galiè  
L Rubin

*12:35 – 14:00 Lunch*

**14:00 – 15:15 Nurse Program: Workshop 1**

The nurse specialist plays a critical role in the evaluation of patients with PAH and monitoring of disease progression, as well as in the management of medications which provide timely and appropriate care. Nurses must often oversee the administration of multiple therapies, some of which require the successful up-titration to an optimal effective dose, while monitoring side effects and avoiding drug-drug interactions. This session will highlight the importance of a multiparameter risk assessment and the impact of disease progression on patients' physical and mental well-being. In addition, the up-titration of therapy, and how to manage side effects and facilitate adherence will be addressed by sharing personal experience and best practices.

*15:15 – 15:30 Switching rooms and coffee break*

## 15:30 – 16:45 Nurse Program: Workshop 2

PAH is a complex, progressive disease. As an essential member in the coordination of multidisciplinary care, the specialist nurse must adapt and change roles in response to the patient's stage of disease, thus allowing the provision of the most suitable care at any given time. In addition, nurse specialists are often the first point of contact for patients and caregivers, illustrating the extent and importance of their support to positively influence a patient's perspective and behavior. This workshop will address how the role of a nurse specialist changes in response to a patient's characteristics and stage of disease. Two interactive patient cases will also be discussed that highlight how these factors influence PAH care and management decisions.

Sunday, 25 March 2018

### 09:00–10:35 Plenary 3:

#### Beyond Group 1 PH – Classification and treatment strategies

**Co-Chairs:**

**JA Barberà, V McLaughlin**

- CTEPH – The small vessel component
- Updates in CTEPH management
- PH due to lung diseases – What is new?
- PH due to left heart disease – The right approach

G Simonneau  
A Ghofrani  
SD Nathan  
JL Vachiéry

10:35 – 11:05 *Coffee break with poster exhibition*

### 11:05 – 12:40 Plenary 4:

#### Making connections – Highlights from the field of PAH

**Co-Chairs:**

**M Delcroix, A Torbicki**

- PAH-CTD from theory to practice – A patient case
- PAH-CTD – From diagnosis to tailored treatment
- PAH associated with drug use – Where do we stand?
- Highlights of the 17th International PH Forum

G Coghlan  
S Gaine  
N Kim  
R Souza

12:40 – 14:40 *Lunch*

### Abstract submission:

Participants are invited to contribute to the scientific programme by submitting abstracts for poster display by Friday, 2 February 2018.



**ACTELION**

A JANSSEN PHARMACEUTICAL COMPANY  
OF *Johnson & Johnson*

This meeting is sponsored and organised by Actelion Pharmaceuticals Ltd  
Actelion Pharmaceuticals Ltd | Gewerbestrasse 16 | 4123 Allschwil | Switzerland  
Phone +41 61 565 65 65 | Fax +41 61 565 65 00 | [www.actelion.com](http://www.actelion.com)